Editor's Note: In the global fight against AIDS, the development of an HIV vaccine has always been a focal point of attention. Recently, Dr. Devin Sok, Vice President of the International AIDS Vaccine Initiative (IAVI), was interviewed by Infectious Diseases Frontier (IIDF)at the AIDS2024 conference. He provided an in-depth analysis of the latest progress and future outlook in HIV vaccine development. Dr. Sok pointed out that although significant achievements have been made in vaccine research, we are still in the very early stages, facing multiple challenges such as the complexity of the disease, variability in the human immune system, and resource limitations. Current research is focused on Phase I clinical trials, assessing vaccine safety and immune responses. Preliminary data shows positive effects, but further validation is required. Scientists are working tirelessly, and the next 5-10 years may witness new breakthroughs.01
IIDF: How would you assess the current progress in HIV vaccine development? Are we nearing the realization of an effective and widely available HIV vaccine?
Dr Sok: Yes, this is indeed a profound and worthy question for discussion. In my view, while we have made considerable achievements in vaccine development, the reality is that we are still in the very early stages. In recent years, there have been numerous advances in vaccine development for various diseases, but most have not demonstrated satisfactory protective efficacy during effectiveness trials. The reasons for this are complex and varied, including the complexity of the disease, differences in the human immune system, and the challenges inherent in vaccine design. From the initial concept in the laboratory to the final effectiveness trials, the process involves countless trials, optimizations, and validations, making it a long and challenging journey.
Currently, we are in the Phase I clinical trial stage of HIV vaccine research. This phase is primarily focused on evaluating the safety and immune response of the vaccine in humans, a critical step in the vaccine development process. Although we have obtained some preliminary data and results, more research is needed to further validate and optimize the vaccine’s efficacy.
With the continuous advancement of technology and our growing understanding of disease mechanisms, there will be many opportunities to accelerate the vaccine development process. We are now testing many new tools, resources, and ideas in clinical trials, all of which hold promise for providing new directions and approaches for future vaccine development. Looking ahead, I believe that within the next 5-10 years, we will prove the concepts of these new tools, resources, and ideas, and hopefully, we will be able to move on to the next phase of effectiveness trials.
02
IIDF: What are the key challenges that have hindered the progress of HIV vaccine research in your view? How can we overcome these challenges?
Dr Sok: Over the past few decades, we have indeed faced numerous challenges in the fields of medicine and biological sciences, ranging from the complexity of the disease to technological limitations and resource constraints. However, I firmly believe that we have overcome many of these challenges, and the successful development of the SARS-CoV-2 vaccine is a powerful testament to this.
Looking back, the journey of HIV research has provided us with valuable experiences and lessons. From the initial identification of the HIV sequence to the eventual revelation of its detailed structure, scientists endured 28 years of arduous exploration. This journey was filled with challenges and uncertainties, but each step laid a solid foundation for subsequent research. In contrast, the development of the SARS-CoV-2 vaccine progressed at an exceptionally rapid pace. In just six months, we achieved groundbreaking advancements, thanks to a combination of factors. Research in the HIV field undoubtedly offered us critical insights and references. By leveraging the experiences and technologies developed during HIV vaccine research, we were able to advance the SARS-CoV-2 vaccine development more efficiently.
Of course, we continue to confront new challenges. Currently, I believe the biggest bottleneck lies in resource limitations. Despite having advanced technologies and extensive knowledge, our progress is hampered by a lack of funding. We need more resources to conduct additional tests, produce more antigens, and carry out trials on larger populations to analyze the results. These aspects are crucial for accelerating the research process, yet they also represent the most significant obstacles we face today.
03
IIDF: What recent breakthroughs in research have given you new hope or direction for the future development of HIV vaccines?
Dr Sok: I believe there is a lot of very exciting data emerging right now, showcasing the tremendous progress we are making in scientific research. I hope I was able to clearly present this data and these advancements during today’s plenary session. Particularly in the field of preclinical research, we are seeing a wealth of promising data and breakthrough findings.
In scientific research, we often formulate various hypotheses and then test them through experiments. However, it is rare to propose a hypothesis, rigorously test it experimentally, and find that it actually works. Most of the time, our hypotheses fail to hold up for various reasons, or the experimental results differ significantly from what we expected. But the current situation is different. Over the past few years, our team has been engaged in some innovative scientific research, proposing new ideas and hypotheses. And now, these ideas and hypotheses have been validated in experiments. We’ve conducted a series of vaccination studies in both animal models, such as macaques, and humans. In these studies, not only did we observe the expected outcomes, but we also discovered some positive effects that exceeded our expectations.
These research advancements mean that we are one step closer to achieving our scientific goals. Our scientific ideas are gradually becoming reality, which is not only exciting but also opens up more possibilities and directions for our future research. I believe that in the coming days, we will continue to achieve more breakthroughs and progress, making greater contributions to human health and well-being. Therefore, I think this is a very exciting time, as it marks substantial achievements in our scientific exploration and foretells the birth of more scientific miracles in the future.
04
IIDF: In the development of HIV vaccines, do we need to consider the specific needs of different populations (e.g., children, the elderly, high-risk groups)? How can we ensure the effectiveness of vaccines across these populations?
Dr Sok: This question touches on the core of our research and is indeed both important and interesting. As you mentioned, we are currently in the Phase I clinical trial stage, which means our research is primarily focused on adults. This is because Phase I trials are mainly designed to assess the safety and immune response of the vaccine, and adult populations are typically considered the most representative subjects for these initial trials.
However, we also recognize that to fully understand the vaccine’s effectiveness, we need to expand our research to include more diverse populations. This is why we have begun conducting trials in various regions around the world, including sub-Saharan Africa and other areas. By comparing trial results across different regions, we aim to verify whether the vaccine’s response is consistent and to identify any regional or population-specific differences.
The International AIDS Vaccine Initiative (IAVI) has made significant progress in this area. Our G002 trial was conducted in the United States, while the G003 trial took place in Rwanda and South Africa. The results from these trials have already provided us with valuable data and insights. Notably, some preliminary data suggest that children and adolescents may produce a better and faster immune response to the vaccine. This is an incredibly exciting discovery because, if further validated, it could greatly accelerate our vaccine research process. After all, if we can find a vaccine that is more effective in children and adolescents, we may be able to offer better protection to a broader population.
05
IIDF: Looking ahead, how do you envision HIV vaccine research being integrated with existing HIV prevention and treatment strategies to more effectively control the spread of HIV?
Dr Sok: This is indeed an excellent question. In recent years, we have come to fully understand that the populations who can benefit from HIV prevention and treatment services are incredibly diverse. Different groups have different needs and lifestyles, so we need to provide more personalized and varied services to meet those needs.
An HIV vaccine, as a crucial tool for preventing HIV, has very specific and unique target characteristics. Compared to other prevention methods, a vaccine should ideally offer long-term, stable protection, which is its greatest advantage. We are working hard to develop a wider range of prevention options to accommodate the diverse needs of people in their everyday lives. These prevention options will include different types of vaccines, more convenient methods of administration, and more personalized prevention strategies.
Integrating an HIV vaccine with existing prevention and treatment strategies will be key to more effectively controlling HIV transmission. By combining the long-term protection offered by vaccines with the immediate benefits of current prevention methods like PrEP (pre-exposure prophylaxis) and ART (antiretroviral therapy), we can create a more robust and comprehensive approach to HIV prevention. This integration will allow us to tailor interventions to individual needs while also addressing the broader public health challenge of reducing HIV transmission on a global scale.
